Northsight Capital Appoints CEO
This article was originally published in Scrip
Northsight Capital Inc. has appointed John B. Hollister CEO. Hollister has over 25 years of commercial management and fundraising experience and held roles at various companies including SmithKline Beecham and Amgen, where he was director and global commercial leader in oncology. Most recently he was CEO and director of NEMUS Bioscience and previously was CEO and chair of medical device company, EGG Spectrum International. He was also senior vice-president for a diagnostic company, Tethys Bioscience.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.